Janux Therapeutics (JANX) Assets Average (2021 - 2026)

Janux Therapeutics (JANX) has 6 years of Assets Average data on file, last reported at $1.0 billion in Q1 2026.

• Assets Average for Q1 2026 came in at $1.0 billion, down 3.91% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.0 billion (down 3.91% YoY), and the FY2025 annual result was $1.0 billion, up 43.08% from the prior year.
• Assets Average held at $1.0 billion in Q1 2026 per JANX's latest filing, from $1.0 billion in the prior quarter.
• Over five years, Assets Average peaked at $1.1 billion in Q1 2025 and troughed at $347.2 million in Q2 2023.
• A 5-year average of $641.5 million and a median of $534.7 million in 2024 frame the typical range for Assets Average.
• The sharpest annual moves came in 2023 and 2024: Assets Average dropped 7.89% in 2023, then soared 128.94% in 2024.
• A 5-year view of Assets Average shows it stood at $369.9 million in 2022, then grew by 3.72% to $383.6 million in 2023, then soared by 128.94% to $878.3 million in 2024, then rose by 15.36% to $1.0 billion in 2025, then rose by 0.17% to $1.0 billion in 2026.
• Business Quant data shows JANX's Assets Average at $1.0 billion in Q1 2026, $1.0 billion in Q4 2025, and $1.0 billion in Q3 2025.